Background
—The role of plasminogen system components in focal cerebral ischemic infarction (FCI) was studied in mice deficient in plasminogen (Plg
−/−
), in tissue or urokinase plasminogen activator (tPA
−/−
or uPA
−/−
), or in plasminogen activator inhibitor-1 or α
2
-antiplasmin (PAI-1
−/−
or α
2
-AP
−/−
).
Methods and Results
—FCI was produced by ligation of the left middle cerebral artery and measured after 24 hours by planimetry of stained brain slices. In control (wild-type) mice, infarct size was 7.6±1.1 mm
3
(mean±SEM), uPA
−/−
mice had similar infarcts (7.8±1.0 mm
3
,
P
=NS), tPA
−/−
mice smaller (2.6±0.80 mm
3
,
P
<0.0001), PAI-1
−/−
mice larger (16±0.52 mm
3
,
P
<0.0001), and Plg
−/−
mice larger (12±1.2 mm
3
,
P
=0.037) infarcts. α
2
-AP
−/−
mice had smaller infarcts (2.2±1.1 mm
3
,
P
<0.0001 versus wild-type), which increased to 13±2.5 mm
3
(
P
<0.005 versus α
2
-AP
−/−
) after intravenous injection of human α
2
-AP. Injection into α
2
-AP
−/−
mice of Fab fragments of affinospecific rabbit IgG against human α
2
-AP, after injection of 200 μg human α
2
-AP, reduced FCI from 11±1.5 to 5.1±1.1 mm
3
(
P
=0.004).
Conclusions
—Plg system components affect FCI at 2 different levels: (1) reduction of tPA activity (
tPA
gene inactivation) reduces whereas its augmentation (
PAI-1
gene inactivation) increases infarct size, and (2) reduction of Plg activity (
Plg
gene inactivation or α
2
-AP injection) increases whereas its augmentation (α
2
-
AP
gene inactivation or α
2
-AP neutralization) reduces infarct size. Inhibition of α
2
-AP may constitute a potential avenue to treatment of FCI.